Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-α in patients with renal cell carcinoma

Journal of Interferon and Cytokine Research

Volumn 28, Issue 5, 2008, Pages 283-286

  Van Gool, A R ^a,b,e   Verkerk, R ^c   Fekkes, D ^a,d   Sleijfer, S ^a   Bannink, M ^a   Kruit, W H J ^a   Van Der Holt, B ^a   Scharpe S ^c   Eggermont, A M M ^a   Stoter, G ^a   Hengeveld, M W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b De Grote Rivieren   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; PROLYL ENDOPEPTIDASE;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE INCREASE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MALE; MENTAL DISEASE; MOOD DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SIDE EFFECT; SLEEP DISORDER; SYMPTOM CHECKLIST 90; THROMBOCYTE COUNT;

AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PSYCHOPATHOLOGY; SERINE ENDOPEPTIDASES;

EID: 44249113633     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0058     Document Type: Article

References (13)

1. Arrindell WA, Ettema H. 2003. Handleiding bij een multidimensionele psychopathologie-indicator. Lisse: Swets & Zeitlinger. 120 p.
2. Bannink M, Fekkes D, Van Gool AR, Kruit WHJ, Sleijfer S, van der Holt B, Eggermont AMM, Stoter S, Hengeveld MW. 2007. Interferon-α influences tryptophan metabolism without inducing psychiatric side effects. Neuropsychobiology 55(3-4):225-231.
3. Bannink M, Kruit WHJ, Van Gool AR, Sleijfer S, van der Holt B, Eggermont AMM, Stoter S, Hengeveld MW. Interferon-α in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics 49(1):56-63.
4. Brandt I, Scharpé S, Lambeir A-M. 2007. Suggested functions for prolyl oligopeptidase: a puzzling paradox. Clin Chim Acta 377(1-2):50-61.
5. Cheng L, Lumb M, Polgar L, Mudge AW. 2005. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 29(2):155-161.
6. Derogatis LR, Lipman RS, Covi L. 1973. SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 9(1):13-28.
7. Fekkes D, Van Gool AR. 2003. Interferon, tryptophan and depression. Acta Neuropsychiatrica 15(1):8-14.
8. Goossens F, De Meester I, Vanhoof G, Scharpé S. 1992. A sensitive method for the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 30(4):235-238.
9. Maes M, Bonaccorso S. 2004. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand 109(2):126-131.
10. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33.
11. Van Gool AR, Kruit WHJ, Engels FK, Stoter G, Bannink M, Eggermont AMM. 2003. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 25(1):11-20.
12. Van Gool AR, van Ojik HH, Kruit WHJ, Mulder PGH, Fekkes D., Bannink M, Scharpé S, Stoter G, Eggermont AMM, Maes M, Verkerk R. 2004. Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-α in high-risk melanoma patients. J Interferon Cytokine Res 24(7):411-415.
13. Williams RSB, Cheng L, Lumb M, Harwood A. 2002. A common mechanism of action for three mood-stabilizing drugs. Nature 417(6886):292-295.